Patent Grant
8669211
The present invention relates generally to methods for enhancing the quality of life of an animal and particularly to using food compositions containing omega-3 polyunsaturated fatty acids for enhancing the quality of life of a senior or super senior animal.
Companion animals such as dogs and cats frequently require differing diets depending on their life stage (age), size, body composition, and breed. Both dog and cat nutrient requirements can be separated into three different life-stages, based on age: growing dogs (or cats), adult dogs (or cats), and senior dogs (or cats). The latter category, senior dogs (or cats), can be further separated into two stages, which include senior (or mature adult) and super senior (or geriatric). Dogs are further separated into different categories for regular breed dogs versus large-breed dogs.
Essential fatty acids, consisting of omega-3 and omega-6 polyunsaturated fatty acids, are critical nutrients for the health of an animal. These nutrients, however, either cannot be made by animals or cannot be made in sufficient amounts to elicit benefits and therefore must be consumed in an animal's diet. See, e.g., Hornstra, G., et al., “Essential fatty acids in pregnancy and early human development”, Eur. J. Obs. & Gyn. and Reprod. Biology, 61:57-62 (1995). It has previously been postulated that Docosahexaenoic Acid (“DHA”), an omega-3 polyunsaturated fatty acid, is effective in increasing the maze-learning ability and brain functions in aged mice. See, Lim, S.-Y., “Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice”, J. Nutr., 130:1629-1632 (2000).
Rogers discusses the theory of the potential use of antioxidants to slow the deterioration of cognitive function, particularly in the elderly. See Rogers, P., “A healthy body, a healthy mind: long-term impact of diet on mood and cognitive function”, Proceedings of the Nutrition Society, 60:135-143 (2001).
Despite the studies and developments relating to improving cognitive abilities, there continues to be a need for methods for enhancing the quality of life of senior animals, as measured by, e.g., enhanced alertness, improved vitality, cartilage protection, maintenance of muscle mass, enhanced digestibility, and improved skin and pelage quality in senior and super senior animals. As previously reported, the super senior pet food composition described herein may be administered to achieve this result. Additionally, we now report herein our surprising discovery that the enhanced quality of life of senior and super senior animals achieved by the administration of the pet food compositions disclosed herein is reflected at the genomic level. Specifically, as described in detail in the Examples below, gene chip data indicate that the expression of genes that encode proteins associated with several biological pathways such as blood clotting and platelet activation and aggregation, bone and muscle integrity, inflammatory responses, cartilage degradation and pain response, DNA damage and repair pathways, neural function, glycogen synthesis and degradation, glycolysis, gluconeogenesis, the pentose phosphate pathway and electron transport are modified, i.e., in general, the majority are beneficially altered through administration to the animal of the super senior pet food compositions described herein.
The invention provides methods for improving the quality of life of senior and super senior animals by feeding the animal a composition comprising at least about 9% by weight protein, at least about 5% by weight fat, and at least about 0.05% by weight of at least one omega-3 polyunsaturated fatty acid.
In one embodiment, the method comprises feeding the animal an amount of a composition effective to enhance the animal's quality of life, wherein enhanced quality of life is evidenced by improvement in one or more characteristics selected from the group consisting of alertness, vitality, cartilage protection, muscle mass maintenance, digestibility, and skin and pelage quality.
In another embodiment, the method comprises feeding the animal a composition comprising at least one omega-3 polyunsaturated fatty acid selected from the group consisting of docosahexaenoic acid (“DHA”) and eicosapentaenoic acid (“EPA”). In an additional embodiment, the method comprises feeding the animal a composition further comprising at least one antioxidant and at least one nutrient selected from the group consisting of choline, manganese, methionine, cysteine, L-carnitine, lysine, and mixtures thereof.
In one embodiment, the method comprises feeding the animal an amount of a composition effective to improve or enhance the animal's quality of life, wherein enhanced quality of life is evidenced by improvement in one or more biological pathways selected from the group consisting of blood clotting and platelet activation and aggregation, bone and muscle integrity, inflammatory responses, cartilage degradation and pain response, DNA damage and repair pathways, neural function, glycogen synthesis and degradation, glycolysis, gluconeogenesis, the pentose phosphate pathway and electron transport.
In another embodiment, the method comprises feeding the animal an amount of a composition effective to enhance the animal's quality of life, wherein enhanced quality of life is evidenced by a change in expression of one or more genes which encode proteins associated with or related to biological pathways selected from the group consisting of blood clotting and platelet activation and aggregation, bone and muscle integrity, inflammatory responses, cartilage degradation and pain response, DNA damage and repair pathways, neural function, glycogen synthesis and degradation, glycolysis, gluconeogenesis, the pentose phosphate pathway and electron transport.
In yet another embodiment, the invention relates to a method to treat an animal suffering from a disorder or disease associated with or related to a biological pathway selected from the group consisting of blood clotting and platelet activation and aggregation, bone and muscle integrity, inflammatory responses, cartilage degradation and pain response, DNA damage and repair pathways, neural function, glycogen synthesis and degradation, glycolysis, gluconeogenesis, the pentose phosphate pathway and electron transport comprising administering to said animal a composition disclosed herein. In one embodiment, said composition comprises at least about 9% by weight protein, at least about 5% by weight fat, and at least about 0.05% by weight of at least one omega-3 polyunsaturated fatty acid. In a further embodiment said composition comprises at least one omega-3 polyunsaturated fatty acid selected from the group consisting of docosahexaenoic acid (“DHA”) and eicosapentaenoic acid (“EPA”). In yet an additional embodiment, the composition further comprises at least one antioxidant and at least one nutrient selected from the group consisting of choline, manganese, methionine, cysteine, L-carnitine, lysine, and mixtures thereof.
In another embodiment, the invention relates to methods of measuring or characterizing the enhancement in the quality of life of an animal, particularly a senior or super senior animal, fed a composition described herein by quantitating the gene expression levels of one or more genes selected from a group consisting of those disclosed in Tables 5-14 in said animal and comparing said levels in the animal to levels in the animal prior to administration of the feed composition.
In a further embodiment, the invention relates to methods to enhance the quality of life of an animal by modulating the expression level of one or more genes listed on Tables 5-14 (i.e., up or down regulation as indicated therein) in an animal in order to mimic the pattern of expression seen in vivo after administration of the pet food compositions of the present invention. It is also contemplated herein that modulating the expression levels of these genes may have therapeutic value with regard to the treatment of diseases or disorders associated with the various biological pathways.
The invention also relates to methods to identify an animal that might benefit from feeding a composition as disclosed herein comprising measuring the gene expression levels of any one or more genes listed in Tables 5-14 in said animal and comparing said levels to the gene expression levels seen in Tables 5-14 wherein an animal with levels different than those seen in Tables 5-14 would be identified as potentially benefiting from feeding a composition of the present invention.
In yet another aspect of the present invention there are provided assay methods and kits comprising the components necessary to detect expression of polynucleotides encoding the genes disclosed herein, or levels of encoded protein, or fragments thereof, in body tissue samples derived from an animal, such kits comprising, e.g., antibodies that bind to said polypeptides, or to fragments thereof, or oligonucleotide probes that hybridize with said polynucleotides. In a preferred embodiment, such kits also comprise instructions detailing the procedures by which the kit components are to be used.
Other and further objects, features, and advantages of the present invention will be readily apparent to those skilled in the art.
It is contemplated that the invention described herein is not limited to the particular methodology, protocols, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention in any way.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices and materials are now described. All publications mentioned herein are incorporated by reference for the purpose of describing and disclosing the materials and methodologies that are reported in the publication which might be used in connection with the invention.
In practicing the present invention, many conventional techniques in molecular biology may be used. These techniques are well known and are explained in, for example, Current Protocols in Molecular Biology, Volumes I, II, and III, 1997 (F. M. Ausubel ed.); Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; DNA Cloning: A Practical Approach, Volumes I and II, 1985 (D. N. Glover ed.); Oligonucleotide Synthesis, 1984 (M. L. Gait ed.); Nucleic Acid Hybridization, 1985, (Hames and Higgins); Transcription and Translation, 1984 (Hames and Higgins eds.); Animal Cell Culture, 1986 (R. I. Freshney ed.); Immobilized Cells and Enzymes, 1986 (IRL Press); Perbal, 1984, A Practical Guide to Molecular Cloning; the series, Methods in Enzymology (Academic Press, Inc.); Gene Transfer Vectors for Mammalian Cells, 1987 (J. H. Miller and M. P. Calos eds., Cold Spring Harbor Laboratory); and Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively).
As used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise.
The terms “senior” or “mature adult” refers to the life-stage of an animal. For small or regular breed canines, the “senior” life stage is from about 7 to about 10 years of age. For felines, the “senior” life stage is from about 7 to about 12 years of age. For large breed canines, over 5 years of age represents “super senior” as described below.
The terms “super senior” or “geriatric” refers to a specific life-stage of an animal. For small or regular breed canines, the super senior stage is any age greater than 10 years of age. For large breed canines, the super senior stage is any age greater than 5 years of age. For felines, the super senior stage is any age greater than 12 years of age.
The term “large breed” canine means a canine that weighs more than 55 pounds when an adult.
The term “regular breed” canine means a canine that weighs less than 55 pounds when an adult.
The term “small breed” canine means a canine that weighs less than 20 pounds when an adult.
The term “super senior pet food composition” refers to any and all of the pet food compositions disclosed herein.
The term “carbohydrate” as used herein includes polysaccharides (e.g., starches and dextrins) and sugars (e.g. sucrose, lactose, maltose, glucose, and fructose) that are metabolized for energy when hydrolyzed. Examples of carbohydrates suitable for inclusion in the compositions disclosed herein include, but are not limited to, corn, grain sorghum, wheat, barley, and rice.
The term “antioxidant” means a substance that is capable of reacting with free radicals and neutralizing them. Illustrative examples of such substances include beta-carotene, selenium, coenzyme Q10 (ubiquinone), luetin, tocotrienols, soy isoflavones, S-adenosylmethionine, glutathione, taurine, N-acetylcysteine, vitamin E, vitamin C, lipoic acid and L-carnitine. Examples of foods containing useful levels of one or more antioxidants include but are not limited to ginkgo biloba, green tea, broccoli, citrus pulp, grape pomace, tomato pomace, carrot spinach, and a wide variety of fruit meals and vegetable meals. It will be understood by one of skill in the art that while units of antioxidants may be provided herein as “ppm”, appropriate amounts of antioxidants may also be provided as “IU/kg” where appropriate and customary for a given antioxidant such as, e.g., Vitamin E.
The terms “beneficial change” in gene expression, or gene expression may be “beneficially altered” and like terms refer to a modification in gene expression (e.g., up or down regulation of mRNA levels) such that levels of proteins encoded by the genes may be correspondingly modified such that an associated biological pathway may be more likely to function normally and with less tendency to reflect pathological changes in the pathway that, e.g., may be typical of a super senior animal. Generally, beneficial changes in gene expression relate to improved health and/or reduced propensity for disease in an animal. As used herein, measuring differences in gene expression “levels” and like terms refer to, e.g., characterizing whether expression of a gene is up or down regulated in an animal compared to a control level.
As used herein, “improving” or “enhancing” the quality of life of an animal refers to as an improvement or enhancement in one or more characteristics selected from a group consisting of alertness, vitality, protection of cartilage, maintenance of muscle mass, digestibility, and skin and pelage quality. Additionally, improvement/enhancement in blood clotting and platelet activation and aggregation, bone and muscle integrity, inflammatory responses, cartilage degradation and pain response, DNA damage and repair pathways, neural function, glycogen synthesis and degradation, glycolysis, gluconeogenesis, the pentose phosphate pathway and electron transport are also contemplated.
An “improvement” or an “enhancement” in a characteristic or biological pathway refers to a modification in said characteristic or biological pathway such that there is a tendency for the characteristic or pathway to appear and/or function normally and with less tendency to reflect pathological changes in the characteristic or pathway that, e.g., may be typical of a super senior animal.
As used herein, methods to “treat” an animal suffering from a disease or disorder is also meant to encompass methods to prevent and/or to ameliorate the disease or disorder as well.
The present invention provides methods for improving or enhancing the quality of life of a senior or super senior animal. The methods comprise feeding the animal a composition comprising at least about 9% by weight protein, at least about 5% by weight fat, and at least about 0.05% by weight omega-3 polyunsaturated fatty acid. The methods are useful for enhancing alertness, improving vitality, protecting cartilage, maintaining muscle mass, enhancing digestibility, and improving skin and pelage quality in a senior or super senior animal. The methods are also useful for improving in an animal one or more biological pathways selected from the group consisting of blood clotting and platelet activation and aggregation, bone and muscle integrity, inflammatory responses, cartilage degradation and pain response, DNA damage and repair pathways, neural function, glycogen synthesis and degradation, glycolysis, gluconeogenesis, the pentose phosphate pathway and the electron transport pathway, such improvements also being reflected in overall beneficial changes at the genomic level. Methods for treating animals suffering from disorders or diseases associated with or related to these biological pathways comprising administering the compositions of the present invention are also contemplated herein.
Without being bound by theory, the benefits of the invention may be the result of physiological effects from the addition of omega-3 polyunsaturated fatty acids to a senior or super senior animal's diet. Similarly, the antioxidants, choline, and other nutrients may play a role in enhancing a senior or super senior animal's quality of life.
Although the methods of the present invention may improve an animal's quality of life by enhancing all of the above described characteristics or improving all of the described biological pathways, it is not necessary to demonstrate substantial improvements in each of the characteristics or pathways to achieve the “enhanced quality of life” as defined herein.
When the compositions are administered to a senior or super senior animal, the animal experiences an enhanced quality of life, e.g., exhibits or experiences one or more of enhanced alertness, improved vitality, protected cartilage, maintained muscle mass, enhanced digestibility, improved skin and pelage quality, as well as improvements in e.g., blood clotting and platelet activation and aggregation, bone and muscle integrity, inflammatory responses, cartilage degradation and pain response, DNA damage and repair pathways, neural function, glycogen synthesis and degradation, glycolysis, gluconeogenesis, the pentose phosphate pathway and the electron transport pathway as indicated by overall beneficial changes at the genomic level. Methods for determining these measurements of quality of life are known to skilled artisans. For example, alertness can be measured by various means, including an analysis of metabolism and antioxidant markers, as well as through clinical studies with follow-up questions to participating pet owners. Potential metabolism markers may include ghrelin, GLP-1, thyroid hormone, and/or growth hormone. Potential markers of antioxidant status may include serum vitamin E, ORAC, glutathione peroxidase, alkanels, and/or cell damage indicators. Further, vitality can be measured by various means, including an analysis of metabolism and antioxidant markers, as well as through clinical studies with follow-up questions to participating pet owners. Similarly, cartilage protection can be measured by various means, including an analysis of arthritis biomarkers. Potential arthritis biomarkers may include type II collagen synthesis, matrix metaloproteinase, osteocalcin, alkaline phosphatase activity, COMP, and fragments of cartilage damage. Muscle mass maintenance can be measured by various means, including an analysis of body composition and digestibility can be measured by various means, including clinical studies with follow-up questions to participating pet owners and animal feeding to determine the percentage of nutrients digested. Skin and pelage quality can be measured by various means, including clinical studies with follow-up questions to participating pet owners. Additionally, as discussed above, improvements in quality of life is also reflected at the genomic level, as evidenced by gene chip data which indicate beneficial changes on the expression of a majority of genes associated with various important biological pathways including blood clotting and platelet activation and aggregation, bone and muscle integrity, inflammatory responses, cartilage degradation and protection and pain response, DNA damage and repair pathways, neural function, glycogen synthesis and degradation, glycolysis, gluconeogenesis, the pentose phosphate pathway and the electron transport pathway. The identities of these genes are provided in the Examples below.
The methods of the invention are useful for enhancing the quality of life of humans and animals, including primates (e.g., monkeys, chimpanzees, etc.), companion animals (e.g., dogs, cats, horses, etc.), farm animals (e.g., goats, sheep, swine, cattle, etc.), laboratory animals (e.g., mice, rats, etc.), birds (e.g., domestic birds such as canaries, parrots, etc. and commercial birds such as chickens, ducks, turkeys, etc.), rodents (e.g., hamsters, guinea pigs, gerbils, rabbits, hedgehogs, ferrets, chinchillas, etc.), and wild, exotic, and zoo animals (e.g., wolves, bears, deer, etc.). In various embodiments, the animal is a cat, a dog, or a horse.
The compositions of the present invention are designed to enhance digestibility and improve chewability. Canine and feline foods are typically formulated based on life stage (age), size, body composition, and breed. Thus, some embodiments of the present invention include compositions that are formulated to address specific nutritional differences between regular or small breed dogs, large breed dogs, and cats.
The invention provides methods utilizing a variety of compositions containing at least one omega-3 polyunsaturated fatty acid. The compositions include foods, supplements, treats, and toys (typically chewable and consumable toys). The methods also provide the compositions to the designated animals over a period of time that is long enough to effectuate the improved quality of life. In one embodiment, the method provides the animal with a composition for at least thirty days.
The compositions for use in the methods of the present invention generally have an omega-3 polyunsaturated fatty acid content of at least about 0.02% (or from about 0.05% to about 10%, or from about 0.1% to about 6%) by weight on a dry matter basis. In some embodiments, the omega-3 polyunsaturated fatty acid is DHA. In other embodiments, the omega-3 polyunsaturated fatty acid is EPA. In still other embodiments, the omega-3 polyunsaturated fatty acid comprises a mixture of DHA and EPA.
In some embodiments, the composition containing omega-3 polyunsaturated fatty acid is a food. Although both liquid and solid foods are provided, solid foods are typically preferred. Foods include both dry foods and wet foods. Some of the non-polyunsaturated fatty acid components of the food, and their preferred proportions, include those listed in Table 1.
In one embodiment, the methods of this invention comprise feeding a super senior animal a composition in an amount effective to enhance the animal's quality of life. Such compositions generally comprise:
In another embodiment, the methods of this invention comprise feeding a super senior regular or small breed canine a composition in an amount effective to enhance the canine's quality of life. The composition generally comprises:
In another embodiment, the methods of this invention comprise feeding a super senior large breed canine a composition in an amount effective to enhance the canine's quality of life. The compositions generally comprise:
In another embodiment, the methods of this invention comprise feeding a super senior feline a composition in an amount effective to enhance the feline's quality of life. The compositions generally comprise:
In another embodiment, the methods of this invention comprise feeding a super senior animal a composition in an amount effective to enhance the animal's alertness and vitality. The composition generally comprises:
In another embodiment, the methods of this invention comprise feeding a super senior regular or small breed canine a composition in an amount effective to enhance the canine's alertness and vitality. The composition generally comprises:
In another embodiment, the methods of this invention comprise feeding a super senior large breed canine a composition in an amount effective to enhance the canine's alertness and vitality. The composition generally comprises:
In another embodiment, the methods of this invention comprise feeding a super senior feline a composition in an amount effective to enhance the feline's alertness and vitality. The composition generally comprises:
In another embodiment, this invention provides a method for improving the quality of life of a senior or super senior small or regular breed canine The method comprises feeding the canine a composition comprising:
In another embodiment, this invention provides a method for improving the quality of life of a senior or super senior large breed canine. The method comprises feeding the canine a composition comprising:
In another embodiment, this invention provides a method for improving the quality of life of a senior or super senior feline. The method comprises feeding the feline a composition comprising:
In a further embodiment, this invention provides a method for improving the quality of life of a senior or super senior animal comprising feeding the animal (e.g., small, regular or large breed canine or feline, as the case may be) a composition comprising the components as indicated in Table 1A below:
The compositions for use in the methods of this invention further comprise at least one nutrient selected from the group consisting of manganese, methionine, cysteine, mixtures of methionine and cysteine, L-carnitine, lysine, and arginine. Specific preferred amounts for each component in a composition will depend on a variety of factors including, for example, the species of animal consuming the composition; the particular components included in the composition; the age, weight, general health, sex, and diet of the animal; the animal's consumption rate, and the like. Thus, the component amounts may vary widely, and may even deviate from the proportions given herein.
The omega-3 fatty acids may be obtained from a variety of sources. One convenient source is fish oils from, for example, menhaden, mackerel, herring, anchovy, and salmon. DHA and EPA are typical fatty acids present in such fish oils, and, together often make up a significant portion of the oil, such as from about 25% to about 38% of the oil.
When the composition is an animal food, vitamins and minerals preferably are included in amounts required to avoid deficiency and maintain health. These amounts are readily available in the art. The National Research Council (NRC), for example, provides recommended amounts of such ingredients for farm animals. See, e.g., Nutrient Requirements of Swine (10th Rev. Ed., Nat'l Academy Press, Washington D.C., 197298), Nutrient Requirements of Poultry (9th Rev. Ed., Nat'l Academy Press, Washington D.C., 1994), Nutrient Requirements of Horses (Fifth Rev. Ed., Nat'l Academy Press, Washington D.C., 1989), Nutrient Requirements of Dogs and Cats (Nat'l Academy Press, Washington D.C., 2006). The American Feed Control Officials (AAFCO), for example, provides recommended amounts of such ingredients for dogs and cats. See American Feed Control Officials, Inc., Official publication, pp. 126-140 (2003). Examples of vitamins useful as food additives include vitamin A, B1, B2, B6, B12, C, D, E, K, H (biotin), K, folic acid, inositol, niacin, and pantothenic acid. Examples of minerals and trace elements useful as food additives include calcium, phosphorus, sodium, potassium, magnesium, copper, zinc, chloride, and iron salts.
The methods of the present invention include compositions that may further contain other additives known in the art. Preferably, such additives are present in amounts that do not impair the purpose and effect provided by the invention. Examples of additives include, for example, substances with a stabilizing effect, processing aids, substances that enhance palatability, coloring substances, and substances that provide nutritional benefits.
Stabilizing substances include, for example, substances that tend to increase the shelf life of the composition. Potentially suitable examples of such substances include, for example, preservatives, antioxidants, synergists and sequestrants, packaging gases, stabilizers, emulsifiers, thickeners, gelling agents, and humectants. Examples of emulsifiers and/or thickening agents include, for example, gelatin, cellulose ethers, starch, starch esters, starch ethers, and modified starches.
Additives for coloring, palatability (“pal enhancers”), and nutritional purposes include, for example, colorants (e.g., iron oxide, such as the red, yellow, or brown forms); sodium chloride, potassium citrate, potassium chloride, and other edible salts; vitamins; minerals; and flavoring. Such additives are known in the art. See, e.g., U.S. Pat. No. 3,202,514. See also, U.S. Pat. No. 4,997,671. Flavorants include, for example, dairy product flavorants (e.g., milk or cheese), meat flavorants (e.g., bacon, liver, beef, poultry, or fish), oleoresin, pinacol, and the various flavorants identified in the trade by a FEMA (Flavor Extract Manufacturers Association) number. Flavorants help provide additional palatability, and are known in the art. See, e.g., U.S. Pat. No. 4,997,672. See also, U.S. Pat. No. 5,004,624. See also, U.S. Pat. No. 5,114,704. See also, U.S. Pat. No. 5,532,010. See also, U.S. Pat. No. 6,379,727. The concentration of such additives in the composition typically may be up to about 5% by weight. In some embodiments, the concentration of such additives (particularly where such additives are primarily nutritional balancing agents, such as vitamins and minerals) is from about 0% to about 2.0% by weight. In some embodiments, the concentration of such additives (again, particularly where such additives are primarily nutritional balancing agents) is from about 0% to about 1.0% by weight.
Supplements include, for example, a feed used with another feed to improve the nutritive balance or performance of the total. Supplements include compositions that are fed undiluted as a supplement to other feeds, offered free choice with other parts of an animal's ration that are separately available, or diluted and mixed with an animal's regular feed to produce a complete feed. The AAFCO, for example, provides a discussion relating to supplements in the American Feed Control Officials, Inc. Official Publication, p. 220 (2003). Supplements may be in various forms including, for example, powders, liquids, syrups, pills, encapsulated compositions, and the like.
Treats include, for example, compositions that are given to an animal to entice the animal to eat during a non-meal time. Treats for canines include, for example, dog bones. Treats may be nutritional, wherein the composition comprises one or more nutrients, and may, for example, have a composition as described above for food. Non-nutritional treats encompass any other treats that are non-toxic.
Toys include, for example, chewable toys. Toys for dogs include, for example, artificial bones. There is a wide range of suitable toys currently marketed. See, e.g., U.S. Pat. No. 5,339,771 (and references disclosed in U.S. Pat. No. 5,339,771). See also, e.g., U.S. Pat. No. 5,419,283 (and references disclosed in U.S. Pat. No. 5,419,283). The invention provides both partially consumable toys (e.g., toys comprising plastic components) and fully consumable toys (e.g., rawhides and various artificial bones). It should be further recognized that this invention provides toys for both human and non-human use, particularly for companion, farm, and zoo animal use, and particularly for dog, cat, or bird use.
A “food” is a nutritionally complete diet for the intended recipient animal (e.g., domestic cat or domestic dog). A “nutritionally complete diet” is a diet that includes sufficient nutrients for maintenance of normal health of a healthy animal on the diet. The methods of this invention utilize compositions that are not intended to be restricted by any specific listing of proteinaceous or fat ingredients or product form. The compositions can be prepared in, for example, a dry, canned, wet, or intermediate moisture form using conventional pet food processes. In some embodiments, the moisture content is from about 10% to about 90% of the total weight of the composition. In other embodiments, the moisture content is from about 65% to about 75% of the total weight of the composition.
In preparing a composition for use with the methods of the present invention, any ingredient (e.g., fish oil) generally may, for example, be incorporated into the composition during the processing of the formulation, such as during and/or after mixing of other components of the composition. Distribution of these components into the composition can be accomplished by conventional means. In one embodiment, ground animal and poultry proteinaceous tissues are mixed with the other ingredients, including fish oils, cereal grains, other nutritionally balancing ingredients, special-purpose additives (e.g., vitamin and mineral mixtures, inorganic salts, cellulose and beet pulp, bulking agents, and the like); and water that is sufficient for processing is also added. These ingredients preferably are mixed in a vessel suitable for heating while blending the components. Heating of the mixture may be effected using any suitable manner, such as, for example, by direct steam injection or by using a vessel fitted with a heat exchanger. Following the addition of the last ingredient, the mixture is heated to a temperature range of from about 50° F. (10° C.) to about 212° F. (100° C.). In some embodiments, the mixture is heated to a temperature range of from about 70° F. (21° C.) to about 140° F. (60° C.). Temperatures outside these ranges are generally acceptable, but may be commercially impractical without use of other processing aids. When heated to the appropriate temperature, the material will typically be in the form of a thick liquid. The thick liquid is filled into cans. A lid is applied, and the container is hermetically sealed. The sealed can is then placed into conventional equipment designed to sterilize the contents. This is usually accomplished by heating to temperatures of greater than about 230° F. (110° C.) for an appropriate time, which is dependent on, for example, the temperature used and the composition.
Methods of the present invention include utilizing compositions that can be prepared in a dry form using conventional processes. In one embodiment, dry ingredients, including, for example, animal protein sources, plant protein sources, grains, etc., are ground and mixed together. Moist or liquid ingredients, including fats, oils, animal protein sources, water, etc., are then added to and mixed with the dry mix. The mixture is then processed into kibbles or similar dry pieces. Kibble is often formed using an extrusion process in which the mixture of dry and wet ingredients is subjected to mechanical work at a high pressure and temperature, and forced through small openings and cut off into kibble by a rotating knife. The wet kibble is then dried and optionally coated with one or more topical coatings which may include, for example, flavors, fats, oils, powders, and the like. Kibble also can be made from the dough using a baking process, rather than extrusion, wherein the dough is placed into a mold before dry-heat processing.
The compositions are also designed to be easier to chew. Canine and feline foods are typically formulated based on life stage (age), size, body composition, and breed. In the methods of this invention, some embodiments of the compositions address specific nutritional differences between super senior regular or small breed dogs, large breed dogs, and cats.
All percentages expressed herein are on a weight by dry matter basis unless specifically stated otherwise.
As noted previously, this invention is directed, in part, to a method for enhancing the quality of life of an animal. The method comprises feeding a senior or super senior animal a composition in an amount effective to enhance alertness, improve vitality, protect cartilage, maintain muscle mass, enhance digestibility, and improve skin and pelage quality. Additionally, we now report herein our surprising discovery that the enhanced quality of life of an animal achieved by administration of the compositions of the present invention is reflected at the genomic level. While it may be that a change in expression of any one gene disclosed in the tables presented below may result in beneficial or deleterious biological effects, the data presented herein indicate that, overall, the observed expression profiles are consistent with the beneficial biological effects seen in vivo after administration of the diets disclosed herein. Specifically, gene chip data indicate that the expression of genes that encode proteins associated with or related to several biological pathways such as blood clotting and platelet activation and aggregation, bone and muscle integrity, inflammatory responses, cartilage degradation and pain response, DNA damage and repair pathways, neural function, glycogen synthesis and degradation, glycolysis, gluconeogenesis, the pentose phosphate pathway and electron transport are, for the most part, beneficially altered through administration to the animal of compositions described herein. Thus, the invention also relates to methods of measuring or characterizing the enhancement in the quality of life of an animal, particularly a senior or super senior animal, fed a composition described herein by quantitating the gene expression levels of one or more genes selected from a group consisting of those disclosed in Tables 5-14 in said animal and comparing said levels in the animal to levels in the animal prior to administration of the feed composition. Quantitation of gene expression may be carried out in numerous ways familiar to one of skill in the art and include such techniques as RT PCR as well as gene chip assays and Northern blotting. Thus, it is contemplated herein that the expression levels detected may be used, for example, in methods to measure enhancement in the quality of life of an animal as disclosed herein.
In another aspect, the present invention relates to kits which comprise:
(a) a polynucleotide of a gene disclosed herein or a fragment thereof;
(b) a nucleotide sequence complementary to that of (a);
(c) a polypeptide encoded by a gene disclosed herein, or a fragment thereof; or
(d) an antibody to a polypeptide encoded by a gene disclosed herein, or a fragment thereof.
It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. The manufacture of kits as described herein and components thereof (e.g., antibody production) may be achieved according to conventional methods.
It is contemplated herein that modulating the expression levels of the genes disclosed herein may have therapeutic value with regard to the treatment of diseases or disorders associated with the various biological pathways. Such determination may be made on a gene by gene basis without undue experimentation, for example, by assessing expression levels in tissues as well as in blood samples, or by assaying expression levels in vitro in cells or cell lines relevant to particular disease states and suitable for such experimentation. In vivo models of disease might also be utilized in such experimentation. The nature of these and other suitable additional assays would be familiar to one of skill in the art. Thus, based on the genomic data disclosed herein, the invention also relates to methods to enhance the quality of life of an animal by modulating the expression level of one or more genes listed on Tables 5-14 (i.e. up or down regulation as indicated therein) in an animal in order to mimic the pattern of expression seen in vivo after administration of the pet food compositions of the present invention.
Modulation of gene expression levels may be achieved through the use of known modulators of gene expression suitable for administration in vivo, including, but not limited to, ribozymes, antisense oligonucleotides, triple helix DNA, RNA aptamers and/or double stranded RNA directed to an appropriate nucleotide sequence of a gene of interest. These inhibitory molecules may be created using conventional techniques by one of skill in the art without undue burden or experimentation. For example, modification (e.g. inhibition) of gene expression may be obtained by designing antisense molecules, DNA or RNA, to the control regions of the genes discussed herein, i.e. to promoters, enhancers, and introns. For example, oligonucleotides derived from the transcription initiation site, e.g., between positions −10 and +10 from the start site may be used. Notwithstanding, all regions of the gene may be used to design an antisense molecule in order to create those which gives strongest hybridization to the mRNA and such suitable antisense oligonucleotides may be produced and identified by standard assay procedures familiar to one of skill in the art.
Similarly, inhibition of gene expression may be achieved using “triple helix” base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J. E. et al. (1994) In: Huber, B. E. and B. I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, N.Y.). These molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.
Ribozymes, enzymatic RNA molecules, may also be used to modulate gene expression by catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered “hammerhead” or “hairpin” motif ribozyme molecules that can be designed to specifically and efficiently catalyze endonucleolytic cleavage of gene sequences.
Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.
Ribozyme methods include exposing a cell to ribozymes or inducing expression in a cell of such small RNA ribozyme molecules (Grassi and Marini, 1996, Annals of Medicine 28: 499-510; Gibson, 1996, Cancer and Metastasis Reviews 15: 287-299). Intracellular expression of hammerhead and hairpin ribozymes targeted to mRNA corresponding to at least one of the genes discussed herein can be utilized to inhibit protein encoded by the gene.
Ribozymes can either be delivered directly to cells, in the form of RNA oligonucleotides incorporating ribozyme sequences, or introduced into the cell as an expression vector encoding the desired ribozymal RNA. Ribozymes can be routinely expressed in vivo in sufficient number to be catalytically effective in cleaving mRNA, and thereby modifying mRNA abundance in a cell (Cotten et al., 1989 EMBO J. 8:3861-3866). In particular, a ribozyme coding DNA sequence, designed according to conventional, well known rules and synthesized, for example, by standard phosphoramidite chemistry, can be ligated into a restriction enzyme site in the anticodon stem and loop of a gene encoding a tRNA, which can then be transformed into and expressed in a cell of interest by methods routine in the art. Preferably, an inducible promoter (e.g., a glucocorticoid or a tetracycline response element) is also introduced into this construct so that ribozyme expression can be selectively controlled. For saturating use, a highly and constituently active promoter can be used. tDNA genes (i.e., genes encoding tRNAs) are useful in this application because of their small size, high rate of transcription, and ubiquitous expression in different kinds of tissues. Therefore, ribozymes can be routinely designed to cleave virtually any mRNA sequence, and a cell can be routinely transformed with DNA coding for such ribozyme sequences such that a controllable and catalytically effective amount of the ribozyme is expressed. Accordingly the abundance of virtually any RNA species in a cell can be modified or perturbed.
Ribozyme sequences can be modified in essentially the same manner as described for antisense nucleotides, e.g., the ribozyme sequence can comprise a modified base moiety.
RNA aptamers can also be introduced into or expressed in a cell to modify RNA abundance or activity. RNA aptamers are specific RNA ligands for proteins, such as for Tat and Rev RNA (Good et al., 1997, Gene Therapy 4: 45-54) that can specifically inhibit their translation.
Gene specific inhibition of gene expression may also be achieved using conventional RNAi technologies. Numerous references describing such technologies exist and include, for example, WO 99/32619; Miller et al. Cell Mol Neurobiol 25:1195-207 (2005); Lu et al. Adv Genet 54:117-42 (2005).
Antisense molecules, triple helix DNA, RNA aptamers and ribozymes of the present invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the genes discussed herein. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6 according to conventional methods. Alternatively, cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues using methods familiar to one of skill in the art. Vectors may be introduced into cells or tissues by many available means, and may be used in vivo, in vitro or ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from an animal and clonally propagated for autologous transplant back into that same animal. Delivery by transfection and by liposome injections may be achieved using methods that are well known in the art.
The instant invention also includes a method to identify an animal that might benefit from feeding a composition as disclosed herein comprising measuring the gene expression levels of any one or more genes listed in Tables 5-14 in said animal and comparing said levels to the gene expression levels seen in Tables 5-14 wherein an animal with levels different than those seen in Tables 5-14 (e.g., up regulated versus down regulated) would be identified as potentially benefiting from feeding a composition of the present invention.
It is also contemplated herein that the invention relates to methods for treating an animal suffering from disorders or disease associated with or relating to any one of more of the following biological pathways: blood clotting and platelet activation and aggregation, bone and muscle integrity, inflammatory responses, cartilage degradation and pain response, DNA damage and repair pathways, neural function, glycogen synthesis and degradation, glycolysis, gluconeogenesis, the pentose phosphate pathway and electron transport comprising administering to the animal a composition of the present invention.
This invention is not limited to the particular methodology, protocols, and reagents described herein because they may vary. Further, the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention. The terms “comprise”, “comprises”, and “comprising” are to be interpreted inclusively rather than exclusively.
Unless defined otherwise, all technical and scientific terms and any acronyms used herein have the same meanings as commonly understood by one of ordinary skill in the art in the field of the invention. Although any methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred methods, devices, and materials are described herein.
All patents, patent applications, and publications mentioned herein are incorporated herein by reference to the extent allowed by law for the purpose of describing and disclosing the compositions, compounds, methods, and similar information reported therein that might be used with the present invention. However, nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
In the specification there have been disclosed typical preferred embodiments of the invention and, although specific terms are employed, they are used in a generic and descriptive sense only and not for purposes of limitation, the scope of the invention being set forth in the following claims. Many modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims the invention may be practiced otherwise than as specifically described.
This invention can be further illustrated by the following examples of preferred embodiments thereof, although it will be understood that these examples are included merely for purposes of illustration and are not intended to limit the scope of the invention unless otherwise specifically indicated.
A composition formulated for senior or super senior regular or small breed canines is described in Table 2.
A composition formulated for senior or super senior large breed canines is described in Table 3.
A composition formulated for senior or super senior felines is described in Table 4.
To further characterize the nutritional benefits of the super senior pet food compositions of the present invention, gene expression profiles from animals fed the compositions compared to control animals are assayed and the results are described in detail below.
Materials and Methods:
Study Design:
Blood samples are drawn from 9 Beagles according to conventional methods before and after feeding for 14 days on Super Senior K9 diet (a total of 18 samples). Each sample taken after the 14 day trial is compared to its own control.
Isolation of Lymphocytes from Canine Blood
Reagents:
4 ml canine blood, heparin or EDTA tubes, Hank's Balanced Salt Solution (Gibco 14175-095), HEPES buffer (Gibco 15630-080), Accu-Paque (Accurate Chemical & Scientific Corp AN3100).
Materials/Equipment:
Transfer pipettes (VWR 14670-147), 14 ml centrifuge tubes w/ caps, 9″ Pasteur pipettes, 1.5 ml microcentrifuge tubes (VWR 20170-038), centrifuge tube racks, microcentrifuge tube rack, waste container, Beckman Coulter Allegra 25R Centrifuge, SN AJC01J015Eppendorf Centrifuge, 5417C.
Solutions:
Hank's Balanced Salt Solution (HBSS) w/25 mM HEPES buffer solution is made by adding 12.8 ml of HEPES buffer solution to a 500 ml bottle of HBSS. Hank's Balanced Salt Solution and Accu-Paque need to be removed from the refrigerator and placed at room temperature at least 30 minutes before beginning the lymphocyte isolation. Both solutions should be place back in the refrigerator (4° C.) immediately following their use.
Procedure:
Deionized H2O, Absolute ethanol (Sigma E7023), RNA Storage Solution (Ambion 7000), RNase Zap® (Ambion 9780), Buffer RLT, Buffer RW1 and Buffer RPE (provided in the RNeasy Mini Kit).
Equipment/Materials:
RNeasy Mini Kit (Qiagen 74104), QIAshredder spin columns (Qiagen 79656), P1000 Pipetman pipette (Rainin), P200 Pipetman pipette (Rainin), 100-100 μl filtered pipette tips (USA Scientific 1126-7810), 1-200 μl filtered pipette tips (USA Scientific 1120-8810), sterile transfer pipettes (VWR 14670-147), 55 ml sterile solution basin (VWR 21007-974), 2 waste containers (one for liquid, one for tips/pipettes), 1.5 ml sterile microcentrifuge tubes (VWR 20170-038), Microcentrifuge tube rack, permanent marker, Eppendorf Microcentrifuge, model #5417C.
Procedure:
Ovation™ Biotin System v1.0 for probe preps.
Protocol:
User Guide (Cat#D01002, version Oct. 27, 2004, NuGEN Technologies, Inc). The experimental procedure is followed as described in the user guide. All probe preparation starts with 50 ng of total RNA.
Genechip Procedures:
The Genechips used for the test is the Canine Genome 2.0 Array (Affymetrix). This Genechip contains 44,000 probe sets. Detailed sequence information for each unique probe identification number is available from the manufacturer.
Gene Expression Analysis:
Normalization is performed using MAS 5 provided in GCOS Affymetrix software (version 1.2). Expression levels for the genes analyzed are indicated on the tables included in the examples below, where an upward facing arrow refers to “up regulation” or increase and a downward facing arrow indicates “down regulation” in gene expression. Similarly, in some tables, upward or downward facing arrows also indicate increases or decreases in activity of certain proteins involved in a particular pathway, and are otherwise self explanatory.
Gene List Selection:
15,411 genes are selected for further analysis based on their “present” calls in at least 9 out of 18 samples.
Results of the gene chip analysis indicate that 1088 genes are differentially expressed between the control and Super Senior diet treated groups. The expression levels of these 1088 genes are statistically significant when grouped by ‘diet’; using a parametric test where the variances is not assumed to be equal (Welch t-test). The p-value cutoff is 0.01 with no multiple testing correction. Under those selection criteria only about 154 genes would be expected to pass the restriction by chance. The genomic data is discussed in detail below.
Results:
Effect of Nutrition on Genes Associated with Pain and Inflammation
Based on an analysis of the gene chip data, at the P<0.01 level, 1,088 genes changed compared to control expression levels (10 were up regulated and the rest down regulated). At the P<0.001 level, data indicate that 35 genes are down regulated in beagles fed the super senior food. Nine of these down regulated genes are identified as related to the inflammatory and pain response. Down regulation of these genes may be predicted to result in pain relief, cartilage protection (less damage) and reduction in inflammatory responses. The compositions disclosed herein may be part of a therapeutic regimen to treat animals suffering from pain and/or inflammatory diseases. These genes and their putative role in inflammation and pain response are provided below in Tables 5-6.
familiaris similar to
familiaris similar to
familiaris similar to
troglodytes LOC461941
familiaris similar to
Homo sapiens mitogen-
Homo sapiens cDNA
Canis familiaris TIMP
familiaris similar to
Effect of Nutrition on Genes Involved in Heart Health and Blood Coagulation
At the P<0.001 and P<0.01 level, 12 genes are identified to be related to heart health through regulation of the eicosanoid pathway and blood coagulation pathway. The genes are responsible for blood coagulation through platelet activation and aggregation. The down regulation of these genes through nutrition can prevent inappropriate blood clotting which may result in heart or brain related disorders. The compositions of the present invention may be part of a therapeutic regimen to treat animals suffering from disorders or diseases of the blood, heart or brain. These genes and their putative role in vivo are described in Tables 7 and 8 below.
Canis familiaris glycoprotein Ib
Canis familiaris angio-associated
Effect of Nutrition on Genes Involved with Muscle and Bone Regulation
Ten down regulated genes are identified as related to body composition through regulation of bone and muscle. The genes spare muscle and bone deterioration by reducing nitric oxide production and glucocorticoid degradation of muscle. Down regulation of these genes results in a decrease in nitric oxide production and glucocorticoid response. The compositions disclosed herein may be part of a therapeutic regimen to treat animals suffering from diseases or disorders associated with or relating to muscle or bone. These genes and their putative role in muscle and bone regulation are detailed in Tables 9 and 10 below.
Effect of Nutrition on Genes Involved with DNA Damage/Protection and Neural Function
Eleven genes are identified that are related to DNA damage/protection and neural function. With regard to the latter, the genes identified are important for rebound potentiation; they are believed to have a potential role in motor learning. Interestingly, of these genes, all were down regulated except for of gamma-aminobutyric acid (GABA) A receptor, gamma 2 which was up regulated. The compositions disclosed herein may be part of a therapeutic regimen to treat animals suffering from diseases or disorders associated with or relating to DNA damage/protection and neural function. The identity of these genes and their putative role in DNA damage/protection and neural function are described in Tables 11 and 12 below.
Homo sapiens gamma-aminobutyric
Homo sapiens PTEN induced
Canis familiaris BCL2-
Effect of Nutrition on Genes Involved with Glucose Metabolism
Twenty four genes associated with glucose metabolism are down regulated in animals fed the super senior diet which would suggest that these animals are utilizing fat (fat oxidation) instead of glucose as a fuel source. The compositions disclosed herein may be part of a therapeutic regime in diabetic animals and/or for obesity prevention or treatment in an animal. These down regulated genes are identified and their putative role in glucose metabolism described in detail below in Tables 13 and 14.
Macaca fascicularis testis
Canis familiaris
Homo sapiens cDNA FLJ30869
Homo sapiens transketolase
Homo sapiens SLIT-ROBO Rho
Homo sapiens cDNA FLJ44038
This application is a divisional application of application Ser. No. 12/176,331, filed on Jul. 18, 2008, now U.S. Pat. No. 8,252,742, issued Aug. 28, 2012, which is a continuation-in-part of pending U.S. patent application Ser. No. 11/813,276, filed Mar. 28, 2008, now U.S. Pat. No. 8,148,325, issued Apr. 3, 2012, which is a US national stage entry under 35 U.S.C. § 371 of International Application No. PCT US 2005/047461 filed Dec. 30, 2005, publication No. WO 2006/074089, which claims priority to U.S. Provisional Application Ser. No. 60/640,890, filed Dec. 30, 2004, each of which is incorporated by reference in its entirety for all purposes.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2980716 | Reed | Apr 1961 | A |
| 3202414 | Burgess | Aug 1965 | A |
| 3946123 | Hanna | Mar 1976 | A |
| 4053647 | Prussin | Oct 1977 | A |
| 4247562 | Bernotavicz | Jan 1981 | A |
| 4898890 | Sato et al. | Feb 1990 | A |
| 4997671 | Spanier | Mar 1991 | A |
| 4997672 | DeSimone | Mar 1991 | A |
| 5004624 | Koschak et al. | Apr 1991 | A |
| 5030458 | Shug et al. | Jul 1991 | A |
| 5114704 | Spanier et al. | May 1992 | A |
| 5118505 | Koltringer | Jun 1992 | A |
| 5292538 | Paul et al. | Mar 1994 | A |
| 5339771 | Axelrod | Aug 1994 | A |
| 5419283 | Leo | May 1995 | A |
| 5455264 | Beisswenger et al. | Oct 1995 | A |
| 5532010 | Spanier et al. | Jul 1996 | A |
| 5569670 | Weischer et al. | Oct 1996 | A |
| 5599835 | Fischer | Feb 1997 | A |
| 5621117 | Bethge et al. | Apr 1997 | A |
| 5624896 | Axworthy | Apr 1997 | A |
| 5723441 | Higley et al. | Mar 1998 | A |
| 5728735 | Ulrich et al. | Mar 1998 | A |
| 5730988 | Womack | Mar 1998 | A |
| 5756088 | Matsuura et al. | May 1998 | A |
| 5851573 | Lepine et al. | Dec 1998 | A |
| 5858024 | De Lacharriere et al. | Jan 1999 | A |
| 5883083 | Harless | Mar 1999 | A |
| 5916912 | Ames et al. | Jun 1999 | A |
| 5932257 | Wright et al. | Aug 1999 | A |
| 5976548 | Hsia et al. | Nov 1999 | A |
| 5976568 | Riley | Nov 1999 | A |
| 5977162 | Seidman | Nov 1999 | A |
| 5981767 | Tanner et al. | Nov 1999 | A |
| 5994393 | Beisswenger et al. | Nov 1999 | A |
| 6039952 | Sunvold et al. | Mar 2000 | A |
| 6080788 | Sole et al. | Jun 2000 | A |
| 6090414 | Passwater | Jul 2000 | A |
| 6117477 | Paluch | Sep 2000 | A |
| 6133323 | Hayek | Oct 2000 | A |
| 6136339 | Gardiner | Oct 2000 | A |
| 6136859 | Hienriksen | Oct 2000 | A |
| 6184227 | Karmali | Feb 2001 | B1 |
| 6190591 | Van Lengerich | Feb 2001 | B1 |
| 6194454 | Dow | Feb 2001 | B1 |
| 6197340 | Byrd et al. | Mar 2001 | B1 |
| 6232346 | Sole et al. | May 2001 | B1 |
| 6264994 | Castillo et al. | Jul 2001 | B1 |
| 6277842 | Carthron | Aug 2001 | B1 |
| 6306392 | Cavazza | Oct 2001 | B1 |
| 6306442 | Sunvold et al. | Oct 2001 | B1 |
| 6310090 | Hayek | Oct 2001 | B1 |
| 6335361 | Hamilton | Jan 2002 | B1 |
| 6365211 | Corrigan | Apr 2002 | B1 |
| 6365622 | Cavazza | Apr 2002 | B1 |
| 6365623 | Perricone | Apr 2002 | B1 |
| 6379727 | Addy | Apr 2002 | B1 |
| 6426362 | Miller et al. | Jul 2002 | B1 |
| 6441024 | Klatt et al. | Aug 2002 | B1 |
| 6447989 | Comper | Sep 2002 | B1 |
| 6448287 | Casciari | Sep 2002 | B1 |
| 6458767 | Murphy-Ullrich et al. | Oct 2002 | B1 |
| 6479069 | Hamilton | Nov 2002 | B1 |
| 6492325 | Cosgrove | Dec 2002 | B1 |
| 6517877 | Gannon | Feb 2003 | B2 |
| 6572888 | Byrd | Jun 2003 | B2 |
| 6572899 | Gorsek | Jun 2003 | B1 |
| 6589748 | Comper | Jul 2003 | B2 |
| 6596762 | Sokol | Jul 2003 | B2 |
| 6599876 | Kojima | Jul 2003 | B2 |
| 6616940 | Sunvold et al. | Sep 2003 | B2 |
| 6746678 | Shapiro | Jun 2004 | B1 |
| 6784159 | Holub et al. | Aug 2004 | B2 |
| 6902739 | McPeak et al. | Jun 2005 | B2 |
| 6914071 | Zicker et al. | Jul 2005 | B2 |
| 6974841 | Rapisarda | Dec 2005 | B1 |
| 7202270 | Majeed et al. | Apr 2007 | B2 |
| 7282225 | Davis et al. | Oct 2007 | B1 |
| 7700139 | Bird et al. | Apr 2010 | B2 |
| 8148325 | Yamka et al. | Apr 2012 | B2 |
| 8252742 | Yamka et al. | Aug 2012 | B2 |
| 20010043983 | Hamilton | Nov 2001 | A1 |
| 20010044448 | Dib | Nov 2001 | A1 |
| 20020006907 | Gardiner et al. | Jan 2002 | A1 |
| 20020028762 | Kojima | Mar 2002 | A1 |
| 20020052402 | Zicker et al. | May 2002 | A1 |
| 20020076469 | Zicker et al. | Jun 2002 | A1 |
| 20020076470 | Zicker et al. | Jun 2002 | A1 |
| 20020110582 | Place et al. | Aug 2002 | A1 |
| 20020115710 | Zicker et al. | Aug 2002 | A1 |
| 20020119182 | Zicker et al. | Aug 2002 | A1 |
| 20020142025 | Hageman | Oct 2002 | A1 |
| 20020183382 | Sokol | Dec 2002 | A1 |
| 20030000477 | Abril | Jan 2003 | A1 |
| 20030007998 | Block et al. | Jan 2003 | A1 |
| 20030035821 | Heaton | Feb 2003 | A1 |
| 20030044466 | Markey | Mar 2003 | A1 |
| 20030060503 | Hamilton | Mar 2003 | A1 |
| 20030068309 | DeSimone | Apr 2003 | A1 |
| 20030138477 | Barclay | Jul 2003 | A1 |
| 20030194478 | Davenport et al. | Oct 2003 | A1 |
| 20030198730 | Stewart | Oct 2003 | A1 |
| 20030224061 | Pacioretty | Dec 2003 | A1 |
| 20040037944 | Cupp et al. | Feb 2004 | A1 |
| 20040047896 | Malnoe et al. | Mar 2004 | A1 |
| 20040068040 | Zicker et al. | Apr 2004 | A1 |
| 20040105879 | Heaton et al. | Jun 2004 | A1 |
| 20040166157 | Thombre | Aug 2004 | A1 |
| 20050026225 | Comper | Feb 2005 | A1 |
| 20050100617 | Malnoe et al. | May 2005 | A1 |
| 20050123628 | Zabrecky | Jun 2005 | A1 |
| 20050232976 | Zicker et al. | Oct 2005 | A1 |
| 20050249787 | Reynolds et al. | Nov 2005 | A1 |
| 20050266051 | Kelley | Dec 2005 | A1 |
| 20050266052 | Bartlett et al. | Dec 2005 | A1 |
| 20060002985 | Zicker | Jan 2006 | A1 |
| 20060134014 | Scherl et al. | Jun 2006 | A1 |
| 20060141011 | Jewell | Jun 2006 | A1 |
| 20070264287 | Zicker et al. | Nov 2007 | A1 |
| 20080038323 | Zicker et al. | Feb 2008 | A1 |
| 20080057039 | Rogers et al. | Mar 2008 | A1 |
| 20080069834 | Zicker et al. | Mar 2008 | A1 |
| 20080206398 | Yamka | Aug 2008 | A1 |
| 20080214653 | Zicker et al. | Sep 2008 | A1 |
| 20080299286 | Josephson et al. | Dec 2008 | A1 |
| 20080317725 | Baum | Dec 2008 | A1 |
| 20080317884 | Jewell | Dec 2008 | A1 |
| 20090004299 | Wedekind et al. | Jan 2009 | A1 |
| 20090047361 | Jewell | Feb 2009 | A1 |
| 20090111877 | Yamka | Apr 2009 | A1 |
| 20090149529 | Zicker et al. | Jun 2009 | A1 |
| 20090155393 | Zicker et al. | Jun 2009 | A1 |
| 20090156658 | Zicker et al. | Jun 2009 | A1 |
| 20090176864 | Zicker et al. | Jul 2009 | A1 |
| 20090182032 | Zicker et al. | Jul 2009 | A1 |
| 20090227665 | Zicker et al. | Sep 2009 | A1 |
| 20090227666 | Jewell | Sep 2009 | A1 |
| 20100076064 | Zicker et al. | Mar 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 1454056 | Nov 2003 | CN |
| 1469712 | Jan 2004 | CN |
| 1617674 | May 2005 | CN |
| 1652696 | Aug 2005 | CN |
| 101128109 | Feb 2008 | CN |
| 101247833 | Aug 2008 | CN |
| 101309596 | Nov 2008 | CN |
| 102170792 | Aug 2011 | CN |
| 0678247 | Oct 1995 | EP |
| 1155627 | Nov 2001 | EP |
| 1350435 | Oct 2003 | EP |
| 2027577 | Feb 1980 | GB |
| S55-19090 | Feb 1980 | JP |
| S57-132849 | Aug 1982 | JP |
| H08-38063 | Feb 1996 | JP |
| 2003-527124 | Sep 2003 | JP |
| 2004-141130 | May 2004 | JP |
| 2007-524402 | Aug 2007 | JP |
| 2131677 | Jun 1999 | RU |
| 200407080 | May 2004 | TW |
| WO 0018247 | Apr 2000 | WO |
| WO 2004024930 | Mar 2004 | WO |
| WO 2005051093 | Jun 2005 | WO |
| WO 2006074089 | Jul 2006 | WO |
| WO 2007002837 | Jan 2007 | WO |
| WO 2007059439 | May 2007 | WO |
| WO 2008018043 | Feb 2008 | WO |
| WO 2009088433 | Jul 2009 | WO |
| Entry |
|---|
| Araujo et al., 2005, “Assessment of nutritional interventions for modification of age-associated cognitive decline using a canine model of human aging,” Age: J. Amer. Aging Assoc. 27(1):27-37. |
| Hall et al., 2005, “Dietary n-30 fatty acids alter plasma fatty acids and leukotriene B synthesis by stimulated neutrophils from healthy geriatric beagles,” Prostaglandins, Leukotrienes and Essential Fatty Acids 73(5):335-341. |
| Hornstra et al., “Essential Fatty Acids in Pregnancy and Early Human Development,” European Journal of Obstetrics & Gynecology and Reproductive Biology (1995) pp. 57-62. |
| Hossain et al., 1999, “Antioxidative effects of docosahexaenoic acid in the cerebrum versus the cerebellum and brainstem of aged hypercholesterolemic rats,” J. Neurochem. 72:1133-1138. |
| International Search Report of the International Application No. PCT/US09/051114, mailed Dec. 1, 2009. |
| International Search Report of the International Searching Authority dated May 10, 2007 for International Application No. PCT/US2005/047461. |
| Kearns et al., 1999, “Effect of age, breed and dietary omega-6 (n-6):omega-3 (n-3) fatty acid ratio on immune function, eicosanoid production and lipid peroxidation in young and aged dogs,” Veter. Immunol Immunopathol. 69:165-183. |
| Lim et al., “Intakes of Dietary Docosahexaenoic Acid Ethyl Ester and Egg Phosphatidylcholine Improve Maze-Learning Ability in Young and Old Mice,” J. Nutrition (2000) 130:1629-1632. |
| Opstvedt, 1985 “Fish Lipids in Animal Nutrition,” ifoma Technical Bulletin, http://www.iffo.net/downloads/Technical%20Bulletins/English/TB22%201ipids%20in%20animal%20nutrition.pdf. |
| Rogers, 2001, “A healthy body, a healthy mind: long-term impact of diet on mood and cognitive function,” Proc. Nutr. Soc. 60:135-143. |
| Number | Date | Country | |
|---|---|---|---|
| 20120289430 A1 | Nov 2012 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60640890 | Dec 2004 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12176331 | Jul 2008 | US |
| Child | 13556925 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11813276 | US | |
| Child | 12176331 | US |
